Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
10.12.2020 16:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.
“NBE-Therapeutics’ iADC platform adds exceptional tumor targeting capabilities to our oncology portfolio. Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel cancer therapies for patients in need. We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work.”
The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones.
“I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics. “We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”
Boehringer Ingelheim’s cancer cell directed research is focused on the development of targeted therapies for the treatment of difficult-to-treat solid tumors. Inducing tumor cell death is a key component, and ADC based approaches have emerged as a powerful targeted therapy with potential for induction of immunogenic cell death at reduced systemic exposure and toxicity.
The NBE-Therapeutics’ acquisition will significantly strengthen Boehringer Ingelheim’s strategic focus on targeted cancer cell-directed therapies and complements existing capabilities in antigen discovery as well as antibody and T-cell engager technologies. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative therapies and accelerating the delivery of the next generation of cancer treatments. This builds on recent strategic acquisitions and collaborations, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are also contributing assets.
NBE-Therapeutics is headquartered in Basel, Switzerland, where it was founded with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund, and PPF Group, as their largest shareholders, and Denmark’s Novo Holdings. NBE-Therapeutics’ technology platform and derived assets are protected by a broad portfolio of patents and licenses.
The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-nbe-therapeutics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005538/en/
Contact information
NBE-Therapeutics
Bertrand Damour, CEO
E: bertrand.damour@NBE-Therapeutics.com
NBE-Therapeutics media enquiries:
Optimum Strategic Communications
Mary Clark, Manel Mateus, Elakiya Rangarajah
T: +44 (0) 20 3922 0900
E: NBE-Therapeutics@optimumcomms.com
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danube Properties Expands UK Presence with New London Office, Eyes Wider European Growth3.6.2026 12:34:00 EEST | Press release
Danube Properties, one of the UAE’s leading real estate developers, is set to strengthen its international presence with the launch of its new sales office in Central London. Located at 44 Brompton Road, Knightsbridge, SW3 1BW, the new office marks another milestone in the company’s growing expansion across the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260530149191/en/ Atif Farid, Head Business Development (UK); Rizwan Sajan, Founder and Chairman of Danube Group; and Adel Sajan, Managing Director of Danube Group, at the launch of Danube Properties' new sales office in Central London. (Photo: AETOSWire) The opening follows the successful launch of Danube Properties’ first UK office in Harrow two years ago, which established a strong connection with investors and homebuyers seeking premium Dubai real estate opportunities. Building on this momentum, the new Knightsbridge office aims to provide enhanced acce
Sensofusion Introduces its Aerospace Unit: Swift Surveillance Aircraft and Fennec Satellites3.6.2026 12:30:00 EEST | Press release
Finnish defence technology company Sensofusion Oy is expanding its operations from the ground to the air and into Earth orbit. As of today, the company's aviation and space business will operate under the name Sensofusion Aerospace.The unit's ongoing product development projects are the Sensofusion Swift surveillance aircraft and the company's first two satellite missions, Fennec-1 and Fennec-2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603447178/en/ With the Fennec-satellite program, Sensofusion's sensing capability extends into Earth orbit. Sensofusion Swift is a type-certified general aviation aircraft with integrated signals intelligence capability, radar and other advanced sensors. Unlike unmanned systems, Swift can operate in peacetime airspace near airports and population centres without separate exemptions. Sensofusion Swift is both an aircraft and a drone. It can be procured and operated either as a crewed g
Swedish Court Reschedules Publication of Judgment in PriceRunner Vs Google Antitrust Case3.6.2026 11:34:00 EEST | Press release
Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from 10 June to 26 June, 2026 at 11:00 CET. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klarna’s litigation funder, and to applicable taxation. The dollar amount of the claim should not be taken as an indication of any likely recovery. This announcement does not constitute a profit forecast. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. These statement
Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 20143.6.2026 11:00:00 EEST | Press release
A new study detailing the scale of the illicit cigarette trade in the European Union (EU) shows that consumption of black-market cigarettes rose more than 7% year-on-year in 2025, reaching levels not seen in over a decade, with counterfeit cigarettes playing an increasingly significant role across member states. Philip Morris International (PMI) (NYSE: PM) reiterates its call for a coordinated response to illicit trade in Europe, built on evidence-based regulation and strengthened cooperation. According to the 20th edition of the study “Illicit cigarette and heated tobacco consumption, and oral nicotine share in Europe”, which was conducted by KPMG LLP on behalf of Philip Morris Products S.A., illicit cigarettes in the EU accounted for more than one in ten cigarettes for the first time since 2014. In 2025, illicit volumes reached 41.8 billion in the EU—representing 10.3% of total consumption—resulting in an estimated €16.7 billion in lost tax revenues. Across the 38 European countries
Veth Propulsion by Twin Disc Unveiled New Streamline ‑ CRP™ at Maritime Industry Event3.6.2026 11:00:00 EEST | Press release
Veth Propulsion by Twin Disc, a global leader in marine propulsion and maneuvering solutions, unveiled a new addition to its portfolio at Maritime Industry, a leading inland shipping tradeshow in the Netherlands, on June 2. Attendees experienced the debut firsthand. The new product, Streamline‑CRP™, is a major step forward in contra‑rotating propulsion technology. It was developed to meet the demand for higher efficiency, reduced emissions and better onboard comfort. It is purpose‑built for passenger cruise vessels and ferries. Streamline‑CRP delivers superior hydrodynamic performance, even in demanding, shallow‑water conditions. Streamline‑CRP is a next-generation azimuth thruster. It builds on Veth Propulsion’s long experience designing and making advanced propulsion systems. “Customers across the marine industry are demanding solutions that deliver both performance and efficiency,” said Bastiaan van Zuijlekom, Managing Director of Veth Propulsion. “Streamline‑CRP responds directly t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom